Carnegie acted as Nordic Selling Agent in IPO of Y-mAbs Therapeutics, Inc. on NASDAQ Global Select Market.
Y-mAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialisation of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including two pivotal-stage product candidates, naxitamab and omburtamab, which target tumors that express GD2 and B7-H3, respectively. Memorial Sloan Kettering Cancer Center, the world’s largest and oldest private cancer institution, is Y-mAbs’ scientific collaboration partner.
Y-mAbs was founded in 2015 by Thomas Gad, father of a neuroblastoma survivor, and today operates out of New York and Hørsholm.